Last updated: July 19, 2026
ecutive summary: Alcon Research Ltd. v. Mylan Pharmaceuticals Inc., No. 1:13-cv-01332, is a US patent infringement dispute in which Alcon asserted Orange Book-listed IP tied to ophthalmic product(s) commercialized by Alcon and Mylan. The case sits in a cluster of early-2010s Hatch-Waxman litigation involving generic or AB-rated ophthalmic entrants. Litigation-specific merits outcomes, asserted patent numbers, claim scope, and final judgment terms are not recoverable from the case caption alone, so an accuracy-safe litigation summary and patent-strength analysis cannot be produced from the provided information.
Alcon Research Ltd. v. Mylan Pharmaceuticals Inc. 1:13-cv-01332: What was the patent infringement dispute about?
No content sufficient to identify the asserted patents, the accused product(s), the asserted claims, or the technical theories is provided beyond the case caption and docket number. Without that, a litigation summary would risk misstating the infringement basis and procedural posture.
Which Alcon patents were asserted in 1:13-cv-01332?
The asserted patent list, publication numbers, expiration dates, and claim categories (composition, formulation, method-of-use, device, or manufacturing) are not available from the provided input.
Which Mylan product(s) were accused?
The accused NDA/ANDA, strength, dosage form, and whether the allegations covered formulation, dosing regimen, or delivery system cannot be determined from the caption alone.
What infringement theories were used (literal infringement vs doctrine of equivalents)?
Pleading-level details (claim charts, infringement contentions, expert declarations, and amended infringement theories) are not available in the provided material.
What patents protect Alcon’s ophthalmic products that Mylan targeted in 1:13-cv-01332?
A patent-protection mapping requires:
- the relevant Alcon product identity,
- its FDA listing and Orange Book patents,
- and the asserted patent numbers in the case.
Those inputs are not included.
How many patents cover the relevant Alcon product(s) on the Orange Book?
Orange Book status depends on the specific NDA/ANDA and strength/package code. The provided input does not identify them.
What are the patent expiration and exclusivity timelines that governed the dispute?
No patent expiration dates, pediatric exclusivity, patent term adjustment, or listed exclusivity are identifiable from the case caption alone.
When does the Alcon v. Mylan patent estate lose exclusivity and generic entry risk peak?
A timeline requires the asserted patent expiries and any relevant statutory exclusivity (5-year, 3-year, orphan, pediatric). The provided input contains none of these.
Which exclusivity dates control first-launch vs full-launch?
Without the drug and listing, first-launch/skinny label sequencing cannot be computed.
What settlement-triggered launch windows applied?
Settlement dates and triggers are not provided.
What is the Orange Book status of the Alcon drug in 1:13-cv-01332?
Orange Book status requires:
- NDA/ANDA number,
- application-holder name,
- and listing-level fields.
Those are not provided.
Is the dispute about an NDA or an ANDA?
The ANDA/NDA identification is not included in the input.
Were any patents listed only for methods of use or formulations?
The listing category cannot be assigned without the Orange Book entries for the specific product.
Was there a Paragraph IV challenge in Alcon Research Ltd. v. Mylan Pharmaceuticals Inc. 1:13-cv-01332?
Whether the case followed Paragraph IV filing mechanics depends on the underlying ANDA notice and the asserted Orange Book patents.
Which patents were the Paragraph IV targets?
Not identifiable from the provided input.
Did the case include a 30-month stay and subsequent stipulations?
No procedural timeline is provided.
How strong is the patent estate for Alcon’s ophthalmic product(s) in this case?
A strength analysis needs:
- claim construction outcomes,
- infringement/non-infringement findings,
- validity rulings (anticipation, obviousness, written description/enablement),
- and any PTAB interactions.
None of these are available from the provided input.
What did the court decide on validity or infringement?
No merits disposition, claim construction order, summary judgment ruling, or trial outcome is available from the input.
Were key evidentiary rulings (experts, prior art, prosecution history) reported?
Not available.
What procedural milestones occurred in the 1:13-cv-01332 docket?
A procedural summary requires docket events: complaint filing date, service, motions to dismiss, amended complaints, discovery milestones, claim construction, summary judgment, trial dates, and final disposition.
None of these details are provided.
Was the case dismissed, settled, or decided on the merits?
Not determinable from the caption alone.
Were there appeals or mandamus petitions?
Not determinable from the input.
What patent litigation affects Mylan’s ophthalmic portfolio after 1:13-cv-01332?
A forward-looking litigation impact analysis requires knowledge of the case resolution and any cross-licensing or estoppel effects, plus Mylan’s subsequent litigation activity.
No resolution facts are provided.
How does Alcon Research Ltd. v. Mylan Pharmaceuticals Inc. compare with other Alcon vs generic ophthalmic litigations?
Comparison requires:
- the specific Alcon product category,
- the pattern of asserted patents,
- and the outcomes.
Those facts cannot be extracted from the input.
Key Takeaways
- The provided information identifies only the parties and docket number: Alcon Research Ltd. v. Mylan Pharmaceuticals Inc., 1:13-cv-01332.
- A litigation summary and patent-strength analysis require asserted patent identities, accused products, Orange Book listing details, and procedural disposition.
- None of these litigation-critical facts are present in the provided input, so an accuracy-safe analysis cannot be produced.
FAQs
- What court and district is 1:13-cv-01332 in?
- What type of IP was typically asserted in Alcon vs Mylan ophthalmic cases (formulation, method-of-use, device)?
- Did the case involve an ANDA Paragraph IV notice and a 30-month stay?
- What is the Orange Book patent listing structure that drives Alcon’s ophthalmic exclusivity fights?
- Which outcomes (settlement, dismissal, summary judgment) most commonly end Alcon ophthalmic patent suits like this one?
References
No sources are available in the provided input to cite.
